TransCode Therapeutics Regains Nasdaq Listing Compliance

TL;DR

TransCode dodged Nasdaq delisting, shares stay listed.

AI Summary

TransCode Therapeutics, Inc. announced on June 10, 2024, that Nasdaq has determined the company has regained compliance with its continued listing requirements. This means TransCode's shares will remain listed on the Nasdaq stock exchange, avoiding delisting. The company is based in Boston, MA.

Why It Matters

This news is crucial for TransCode Therapeutics as it ensures continued trading on a major stock exchange, maintaining liquidity and investor confidence.

Risk Assessment

Risk Level: medium — While regaining listing is positive, the company's financial health and ability to meet future listing requirements remain a concern.

Key Players & Entities

• TransCode Therapeutics, Inc. (company) — Registrant
• Nasdaq (company) — Stock Exchange
• 0001104659-24-069885.txt (document) — SEC Filing Identifier
• June 10, 2024 (date) — Announcement Date
• BOSTON (location) — Company Headquarters

FAQ

Key Financial Figures

• $1.00 — ur current share price closing over the $1.00 Nasdaq minimum bid price, the Company d

Filing Documents

• tm2416749d2_defa14a.htm (DEFA14A) — 15KB
• tm2416749d2_defa14a-img01.jpg (GRAPHIC) — 15KB
• 0001104659-24-069885.txt ( ) — 37KB

Forward-Looking Statements

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the continued listing of the Company’s stock on the Nasdaq Capital Market. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with drug discovery and development; risks that the results of clinical trials we conduct will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus and geopolitical events. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors&rdqu

View Full Filing

View this DEFA14A filing on SEC EDGAR